Clinical trial · Observational
Clinical Registration Study of Haplo-HSCT for Elderly Patients With Acute Leukemia/ Myelodysplastic Syndrome
Clinical Registration Study of Haploidentical Stem Cell Transplantation for Elderly Patients With Acute Leukemia or Myelodysplastic Syndrome
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is an open, prospective, single-center, single-arm study expanded based on the study of NCT03412409.The primary objective of this study is to evaluate the transplantation efficacy of the RIC conditioning regimen in elderly patients receiving the transplantation of haploidentical hematopoietic stem cells. Elderly patients are defined as ≥55 years of age; High comorbidity is defined as an HCT-CI score ≥3.Primary endpoint is 1-year LFS. Secondary endpoints are 1-year OS and 1-year TRM, Other indicators to be assessed in this study include acute GVHD, chronic GVHD, CMV activation, EBV activation, engraftment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Leukemia | Acute Leukemia | ONTOLOGY_EXACT | 0.90 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- RIC regimen,Elderly,Haplo-HSCT,PFS,OS,TRM
Primary outcomes (1)
- measure
- 1-year LFS
- timeFrame
- Participants will be followed for an expected average of 1 years
- description
- defined as disease relapse, disease progression or death (whichever occurs first) within 1 year from the day the patient receives transplantation.
Secondary outcomes (2)
- measure
- 1-year OS
- timeFrame
- Participants will be followed for an expected average of 1 years
- description
- defined as survival rate within 1 year from the day the patient receives transplantation, calculated based on death from any cause.
- measure
- 1-year TRM
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 55 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Patients ≥55 years of age and \<70 years of age, with acute leukemia or MDS (with or without HCT-CI≥3); * Patients eligible for the transplantation of allogeneic hematopoietic stem cells; * Patients unavailable with HLA matched donors but available with haploidentical donors; * Voluntary participation in this study and signing the informed consent form. Exclusion Criteria: * Patients with the severe infections; * Pregnant or lactating women or female and male subjects of childbearing age and their spouses who are unable to secure effective contraception during the dosing period and within 90 days after the end of the dosing period. * Patients who are not eligible for hematopoietic stem cell transplantation; * Patients who are enrolled in other clinical trials within 1 month; * Patients who may not be able to complete the study for other reasons, or may be considered by the investigator not suitable to participate in the study; * Patients unable to properly understand or refusing to accept the informed consent form.
References
Publications (0)
Data not yet available